trastuzumab-anns
| Brand name | Kanjinti |
|---|---|
| Active ingredient | trastuzumab-anns |
| Strength | 150MG |
| Dosage form | For Injection |
| Route | Intravenous |
| Modality | Biologic |
| FDA approval | October 2019 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.